Angiotensin II receptor antagonists in acute coronary syndromes

European Journal of Clinical Investigation

Volumn 44, Issue 2, 2014, Pages 219-230

  Artom, Nathan ^a   Montecucco, Fabrizio ^a,b   Mach, François ^c   Dallegri, Franco ^a   Pende, Aldo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Acute coronary syndromes; Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BRADYKININ; CANDESARTAN; CAPTOPRIL; CGEN 856 S; DEXTRO PROLINE 7 ANGIOTENSIN [1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FONSARTAN; FOSINOPRIL; ICATIBANT; LOSARTAN; MYOSIN HEAVY CHAIN ALPHA; NITRIC OXIDE; OLMESARTAN; PERINDOPRIL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; XNT; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); PHYSIOLOGY; RISK FACTOR; VASCULAR REMODELING;

ACUTE CORONARY SYNDROME; ANGIOTENSIN RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED; RISK FACTORS; VASCULAR REMODELING;

EID: 84892479695     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12198     Document Type: Review

References (90)

1. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implication of more than a century of research. J Renin Angiotensin Syst 2006;7:3-14.
2. Harrison DG, Gongora MC. Oxydative stress and hypertension. Med Clin North Am 2009;93:621-35.
3. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanism and therapeutic interventions. Clin Sci 2007;112:375-84.
4. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
5. Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 1985;313:1330-40.
6. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.
7. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2007;86:747-803.
8. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res 2007;73:463-9.
9. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 2007;16:122-8.
10. Shanmugam S, Llorens-Cortes C, Clauser E, Corvol P, Gasc JM. Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. Am J Physiol 1995;268:F922-30.
11. Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol Int 1996;20:169-76.
12. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.
13. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Syst 2010;11:19-31.
14. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-35.
15. Katada J, Majima M. AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002;136:484-91.
16. Bergaya S, Hilgers RH, Meneton P, Dong Y, Bloch-Faure M, Inagami T et al. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res 2004;94:1623-9.
17. Hein L. Genetic deletion and overexpression of angiotensin II receptors. J Mol Med 1998;76:756-63.
18. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-7.
19. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995;377:748-50.
20. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998;101:527-35.
21. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Nat Acad Sci 1995;92:10663-7.
22. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.
23. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996;28:635-40.
24. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997;96:3954-62.
25. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.
26. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182-91.
27. Tiyerili V, Mueller CF, Becher UM, Czech T, van Eickels M, Daiber A et al. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knockout mice. J Mol Cell Cardiol 2012;52:630-7.
28. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010;30:1606-13.
29. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008;118:2523-32.
30. Koïtka A, Cao Z, Koh P, Watson AM, Sourris KC, Loufrani L et al. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 2010;53:584-92.
31. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2011;52:11-34.
32. Kupfahl C, Pink D, Friedrich K, Zurbrügg HR, Neuss M, Warnecke C et al. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000;46:463-75.
33. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 2001;37:1461-6.
34. Lu L, Quinn MT, Sun Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem Biophys Res Commun 2004;325:943-51.
35. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998;30:1559-69.
36. 1. J Mol Cell Cardiol 2001;33:969-81.
37. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994;28:1423-32.
38. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 1994;28:1623-8.
39. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K et al. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol 1995;27:1905-14.
40. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 1999;33:961-8.
41. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
42. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
43. Wang B, Ansari R, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. The scar neovasculature after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2005;289:H108-13.
44. Kohno T, Anzai T, Naito K, Sugano Y, Maekawa Y, Takahashi T et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 and macrophage infiltration in post-infarction ventricular remodeling. Circ J 2008;72:1685-92.
45. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of combination of angiotensin converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001;38:1207-15.
46. Noda K, Kobara M, Hamada J, Yoshifuji Y, Shiraishi T, Tanaka T et al. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J Cardiovasc Pharmacol 2012;60:140-9.
47. Xia QG, Chung O, Spitznagel H, Illner S, Jänichen G, Rossius B et al. Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res 2001;49:110-7.
48. Babick A, Chapman D, Zieroth S, Elimban V, Dhalla NS. Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. J Cell Mol Med 2012;16:2958-67.
49. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang JJ, Bader M et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 2009;94:322-9.
50. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 2004;109:2143-9.
51. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor. Am J Hypertens 1992;5:276-80.
52. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
53. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 1995;25:1252-9.
54. Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H et al. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens 2011;29:2236-45.
55. Fraga-Silva RA, Montecucco F, Mach F, Santos RA, Stergiopulos N. Pathophysiological role of the renin-angiotensin system on erectile dysfunction. Eur J Clin Invest 2013;43:978-85.
56. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail. 2010;3:286-93.
57. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010;56:112-20.
58. Fraga-Silva RA, Costa-Fraga FP, Murça TM, Moraes PL, Martins Lima A, Lautner RQ et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 2013;61:1233-8.
59. Zhang T, Li Z, Dang H, Chen R, Liaw C, Tran TA et al. Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012;302:H299-311.
60. Jneid H, Anderson JL, Scott Wright R, Adams CD, Bridges CR, Casey DE Jr et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). Circulation 2012;126:875-910.
61. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
62. Waeber B, Brunner HR. Cardiovascular hypertrophy: role of angiotensin II and bradykinin. J Cardiovasc Pharmacol 1996;27:S36-40.
63. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.
64. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010;105:10A-20A.
65. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
66. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM et al. Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest 1993;91:1269-81.
67. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
68. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11:13F-9F.
69. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
70. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med 2003;349:1839-906.
71. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000;342:145-53.
72. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the Europa study). Lancet 2003;362:782-8.
73. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9.
74. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005;26:2381-6.
75. Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009;27:941-6.
76. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
77. Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45:46-52.
78. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2003;108:684-90.
79. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
80. Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA et al. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Press 2008;17:170-7.
81. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11.
82. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
83. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II receptors blockers for ischemic heart disease. Ann Intern Med 2009;151:861-71.
84. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131-42.
85. Nishino T, Furukawa Y, Kaji S, Ehara N, Shiomi H, Kim K et al. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction. Circ J 2013;77:1242-52.
86. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-9.
87. Radke PW, Figulla HR, Drexler H, Klues HG, Mügge A, Silber S et al. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006;152:761.e1-6.
88. Yokoyama J, Higuma T, Tomita H, Abe N, Oikawa K, Fujiwara T et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol 2009;132:114-20.
89. Pelliccia F, Pasceri V, Cianfrocca C, Vitale C, Speciale G, Gaudio C et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2010;210:510-5.
90. Pende A, Dallegri F. Classical and new renin-angiotensin signalling in atherosclerosis. Curr Signal Trans Therapy 2012;7:111-9.